20170503 - Blueprint Genetics Breakfast Seminar

Defining transparency in a genetic testin

At the end of the session, the participants will be able to:
• Gain an understanding of the limitations in current genetic testing technologies
• Define and understand what transparency from a lab means
• Discuss the results of the analytic validation of the Blueprint Genetics diagnostics pipeline and the diagnostic yield encountered so far

Question Title

* 1. Please rate the Session by circling the appropriate number:
Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree

	1	2	3	4	5
Sufficient time was allowed for audience participation/active learning	Sufficient time was allowed for audience participation/active learning 1	Sufficient time was allowed for audience participation/active learning 2	Sufficient time was allowed for audience participation/active learning 3	Sufficient time was allowed for audience participation/active learning 4	Sufficient time was allowed for audience participation/active learning 5
The facilities were satisfactory.	The facilities were satisfactory. 1	The facilities were satisfactory. 2	The facilities were satisfactory. 3	The facilities were satisfactory. 4	The facilities were satisfactory. 5
The session was free from commercial bias	The session was free from commercial bias 1	The session was free from commercial bias 2	The session was free from commercial bias 3	The session was free from commercial bias 4	The session was free from commercial bias 5
Overall, I would rate this Symposium as excellent	Overall, I would rate this Symposium as excellent 1	Overall, I would rate this Symposium as excellent 2	Overall, I would rate this Symposium as excellent 3	Overall, I would rate this Symposium as excellent 4	Overall, I would rate this Symposium as excellent 5

Question Title

* 2. Please asses the Speakers by circling the appropriate number.
Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 Outstanding
Dr. Tero-Pekka Alastalo, MD, PhD

	1	2	3	4	5
Clarity of	Clarity of 1	Clarity of 2	Clarity of 3	Clarity of 4	Clarity of 5
Met Stated Objectives	Met Stated Objectives 1	Met Stated Objectives 2	Met Stated Objectives 3	Met Stated Objectives 4	Met Stated Objectives 5
Balanced & Unbiased	Balanced & Unbiased 1	Balanced & Unbiased 2	Balanced & Unbiased 3	Balanced & Unbiased 4	Balanced & Unbiased 5
Relevant to Practice Overall	Relevant to Practice Overall 1	Relevant to Practice Overall 2	Relevant to Practice Overall 3	Relevant to Practice Overall 4	Relevant to Practice Overall 5
Time for Active Learning	Time for Active Learning 1	Time for Active Learning 2	Time for Active Learning 3	Time for Active Learning 4	Time for Active Learning 5

Question Title

* 3. As a result of attending this session, I am planning to: (please check one)

	YES	NO
a) Discuss the session with my colleagues	a) Discuss the session with my colleagues YES	a) Discuss the session with my colleagues NO
b) Pursue additional learning activities.	b) Pursue additional learning activities. YES	b) Pursue additional learning activities. NO
c) Complete a Personal Learning Project.	c) Complete a Personal Learning Project. YES	c) Complete a Personal Learning Project. NO
d) Not change my practice.	d) Not change my practice. YES	d) Not change my practice. NO
e) Change my practice.	e) Change my practice. YES	e) Change my practice. NO

Question Title

* 4. Please explain the change you are planning to make or the learning you plan to complete:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Medical Expert

Communicator

Collaborator

Manager

Health Advocate

Scholar

Professional

20170503 - Blueprint Genetics Breakfast Seminar

Defining transparency in a genetic testin

Question Title

* 1. Please rate the Session by circling the appropriate number:
Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree

Question Title

* 2. Please asses the Speakers by circling the appropriate number.
Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 Outstanding
Dr. Tero-Pekka Alastalo, MD, PhD

Question Title

* 3. As a result of attending this session, I am planning to: (please check one)

Question Title

* 4. Please explain the change you are planning to make or the learning you plan to complete:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers

Question Title

* 7. What topics need to be addressed at future conferences to keep you up to date in your profession?

Question Title

* 1. Please rate the Session by circling the appropriate number:Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree

Question Title

* 2. Please asses the Speakers by circling the appropriate number.Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 OutstandingDr. Tero-Pekka Alastalo, MD, PhD

Question Title

* 3. As a result of attending this session, I am planning to: (please check one)

Question Title

* 4. Please explain the change you are planning to make or the learning you plan to complete:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers

Question Title

* 7. What topics need to be addressed at future conferences to keep you up to date in your profession?

* 1. Please rate the Session by circling the appropriate number:
Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree

* 2. Please asses the Speakers by circling the appropriate number.
Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 Outstanding
Dr. Tero-Pekka Alastalo, MD, PhD